Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Monday morning,Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.00.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $0.29 on Monday. The firm has a market cap of $72.05 million, a P/E ratio of -0.39 and a beta of 1.04. The firm’s fifty day moving average is $0.76 and its 200 day moving average is $1.17. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.83. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Bayesian Capital Management LP purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth approximately $31,000. RPO LLC bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $33,000. Renaissance Technologies LLC purchased a new stake in Lexicon Pharmaceuticals in the fourth quarter worth $38,000. Arizona State Retirement System grew its position in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in shares of Lexicon Pharmaceuticals by 60.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 24,615 shares in the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.